Skip to content

SpyGlass Pharma, Inc.

SGP

CIK 0001778922

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$39.87M
−36.7% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$17.98
−10.2% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$33.49M
Q1 Apr 2026
Cash
$238.9M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
33.43M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings